Venetoclax Patent Expiration
Venetoclax is Used for treating various forms of leukemia, particularly acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), in adults with certain conditions or as subsequent therapy. It was first introduced by Abbvie Inc
Venetoclax Patents
Given below is the list of patents protecting Venetoclax, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Venclexta | US10993942 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | Sep 06, 2033 | Abbvie |
| Venclexta | US11110087 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor | Sep 06, 2033 | Abbvie |
| Venclexta | US11413282 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | Sep 06, 2033 | Abbvie |
| Venclexta | US11590128 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | Sep 06, 2033 | Abbvie |
| Venclexta | US9539251 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor | Sep 06, 2033 | Abbvie |
| Venclexta | US11369599 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | May 23, 2032 | Abbvie |
| Venclexta | US8722657 | Salts and crystalline forms of an apoptosis-inducing agent | Jan 29, 2032 | Abbvie |
| Venclexta | US10730873 | Salts and crystalline forms of an apoptosis-inducing agent | Nov 21, 2031 | Abbvie |
| Venclexta | US8546399 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | Jun 27, 2031 | Abbvie |
| Venclexta | US9174982 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | May 26, 2030 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Venetoclax's patents.
Latest Legal Activities on Venetoclax's Patents
Given below is the list recent legal activities going on the following patents of Venetoclax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 19 Jul, 2024 | US11369599 |
| Email Notification Critical | 19 Jul, 2024 | US11369599 |
| Mail-Petition Decision - Denied | 16 Jul, 2024 | US11369599 |
| Mail-Petition Decision - Granted | 16 Jul, 2024 | US11369599 |
| Petition Decision - Denied | 15 Jul, 2024 | US11369599 |
| O.P. Petition Decision | 15 Jul, 2024 | US11369599 |
| Petition Decision - Granted Critical | 15 Jul, 2024 | US11369599 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9539251 |
| Electronic Review Critical | 07 Jun, 2024 | US11369599 |
| Petition Entered | 30 Apr, 2024 | US11369599 |
Venetoclax's Family Patents
